InvestorsHub Logo

Lykiri

05/01/23 8:37 AM

#589865 RE: flipper44 #589804

Flipper44,

Four years ago, May 28, 2019, the patient had her first craniotomy to remove a large brain tumor in her right frontal lobe.
After surgery the tumor was confirmed as a Grade IV Glioblastoma.
Shortly thereafter she had a surprise second craniotomy for an infection, complete with severe pain from post herpetic neuralgia, a blood clot, lymphedema, not to mention six weeks of daily radiation and chemotherapy.

On May 21, 2021 she was officially enrolled in the clinical trial. https://clinicaltrials.gov/ct2/show/NCT04201873?cond=atl-dc&draw=2&rank=1

She had her first infusion of the “immunotherapy drug” (Pembrolizumab or Placebo) 14 days before her surgery on June 7, 2021.
About a month after surgery she received three doses of the vaccine DCVax-L across 6 weeks.

On May 28, 2021 she wrote:

“I'm still in shock that this is happening again and so relieved that I was able to be given the LAST SPOT in the clinical trial, which I hope will lead to a cure for Glioblastoma.”


Hard to know what “last spot” means. I think she was the last patient who could be enrolled before the summer holidays. If my reasoning is correct, this patient is censored between 410 - 420 days after surgery on the blue line. My guess is the data were collected at the end of July - first week of August 2022.

Conversation from 7 weeks ago:

Hi …! How are you doing?


Reply from patient enrolled in the COMBO trial:

I’m doing good overall!!! You?